Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 11/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TACR2 | P21452 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 2/20 | 0.37 |
| ▸ | CTSK | P43235 | 2/20 | 0.37 |
| ▸ | CTSL | P07711 | 2/20 | 0.37 |
| ▸ | CTSH | P09668 | 1/20 | 0.37 |
| ▸ | CTSC | P53634 | 1/20 | 0.37 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.37 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.37 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.37 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.37 |
| ▸ | PSMA2 | P25787 | 1/20 | 0.37 |
| ▸ | PSMA3 | P25788 | 1/20 | 0.37 |
| ▸ | PSMA4 | P25789 | 1/20 | 0.37 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5528017 | 0.87 | CTSS (0.43) | CTSSTAS1R3TAS1R1GAATACR2 | |
| SCHEMBL3199921 | 0.84 | CTSS (0.56) | CTSSGAACTSBCTSKCTSL | |
| SCHEMBL3194104 | 0.82 | CTSS (0.44) | CTSSGAACTSLPOLBPSMB11 | |
| SCHEMBL5520908 | 0.82 | PTPN1 (0.46) | CTSSTAS1R3TAS1R1CTSBCTSK | |
| SCHEMBL2302941 | 0.82 | CTSS (0.44) | CTSSGAACTSBCTSKCTSL | |
| SCHEMBL2299523 | 0.82 | CTSS (0.50) | CTSSCTSLPOLBPSMB11PSMA7 | |
| SCHEMBL2302161 | 0.80 | CTSS (0.45) | CTSSGAACTSBCTSKCTSL | |
| SCHEMBL5524933 | 0.80 | TAS1R3 (0.42) | TAS1R3TAS1R1KDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL15389344 | 0.79 | CTSS (0.42) | CTSSGAACTSBCTSKCTSL | |
| SCHEMBL2295546 | 0.77 | TAS1R3 (0.38) | TAS1R3TAS1R1NPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531526-B2 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-05-12 | — | — | US | disclosed |
| US-20080132678-A1 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-20070282100-A1 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-7119080-B2 | For use as inhibitors of proteasome; for reducing the rate of degradation of proteins in an animal | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| US-20060122390-A1 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | US | disclosed |
| EP-1312609-B1 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARM INC (US) | 2005-12-28 | — | — | EP | disclosed |
| US-6617317-B1 | Reducing the rate of degradation of proteins in an animal | MILLENNIUM PHARMACEUTICALS, INC. | 2003-09-09 | — | — | US | disclosed |
| US-6465433-B1 | SUCH AS N-(2-PYRIDINE)CARBONYL-L-PHENYLALANINE-L-LEUCINE BORONIC ACID; PROTEASOME INHIBITORS; REDUCING RATE OF MUSCLE PROTEIN DEGRADATION | MILLENNIUM PHARMACEUTICALS, INC. | 2002-10-15 | — | — | US | disclosed |
| US-6066730-A | Boronic ester and acid compounds, synthesis and uses | PROSCRIPT, INC. | 2000-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122390-A1 | Boronic ester and acid compounds, synthesis and uses | BCL6, BCAP31, CD79B | CTSS 2481/4885TAS1R3 4301/4885TAS1R1 4268/4885 |
| US-20070282100-A1 | Boronic ester and acid compounds, synthesis and uses | BCL6, BCAP31, CD79B | CTSS 2481/4885TAS1R3 4301/4885TAS1R1 4268/4885 |
| US-20080132678-A1 | Boronic ester and acid compounds, synthesis and uses | BCL6, BCAP31, CD79B | CTSS 2481/4885TAS1R3 4301/4885TAS1R1 4268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.